A Phase 2 Open Label Study of Abiraterone Acetate (JNJ-212082) and Prednisolone in Patients With Advanced Prostate Cancer Who Have Failed Androgen Deprivation and Docetaxel-Based Chemotherapy
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 24 Jun 2017
At a glance
- Drugs Abiraterone acetate (Primary) ; Prednisolone
- Indications Prostate cancer
- Focus Therapeutic Use
- Sponsors Janssen Research & Development
- 10 Jun 2017 Biomarkers information updated
- 19 Sep 2016 Planned End Date changed from 1 Sep 2016 to 1 Nov 2020.
- 28 Jul 2015 Planned End Date changed from 1 Sep 2015 to 1 Sep 2016 as reported by ClinicalTrials.gov record.